David C. Portnoy

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn et al. · The Lancet Oncology · 2015 · 938 citations

Oncology, Colorectal Cancer, Pathology +7

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018

Gregory P. Kalemkerian, Billy W. Loo, Wallace Akerley et al. · Journal of the National Comprehensive Cancer Network · 2018 · 294 citations · Full text

Treatment of Intestinal Cryptosporidiosis with Spiramycin

David C. Portnoy · Annals of Internal Medicine · 1984 · 155 citations

Primary Immunodeficiency, Nine Male Patients, Medicine +15

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Ari M. Vanderwalde, Shay Bellasea, Kari Kendra et al. · Nature Medicine · 2023 · 150 citations · Full text

Medicine, Melanoma, Pharmacology +8

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

Josep Tabernero, Rebecca R. Hozak, Takayuki Yoshino et al. · Annals of Oncology · 2017 · 101 citations · Full text